| Bcl11b prevents fatal autoimmunity by promoting Treg cell program and constraining innate lineages in Treg cells TT Drashansky, E Helm, Z Huo, N Curkovic, P Kumar, X Luo, ... Science advances 5 (8), eaaw0480, 2019 | 24 | 2019 |
| Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome JJD Ho, TA Cunningham, P Manara, CA Coughlin, A Arumov, ER Roberts, ... Cell reports 37 (2), 2021 | 19 | 2021 |
| Ocular surface itch and pain: key differences and similarities between the two sensations S Raolji, P Kumar, A Galor Current Opinion in Allergy and Clinical Immunology, 10.1097, 2023 | 2 | 2023 |
| Diffuse large B‐cell lymphoma cell‐cycle progression requires the cyclin‐G associated kinase (GAK), a novel drug target from machine learning‐enabled phenotypic screening OB Lightfuss, A Newsam, P Kumar, L Li, A Ghoshal, AY Alaoui, S Schürer, ... Hematological Oncology 41, 546-546, 2023 | | 2023 |
| The Cyclin-G Associated Kinase (GAK) Is a Critical Dependency for Cell-Cycle Progression in Diffuse Large B-Cell Lymphoma Associated with Deregulation of the Retinoblastoma … AD Newsam, P Kumar, OB Lightfuss, L Li, A Ghoshal, S Schürer, ... Blood 140 (Supplement 1), 2261-2262, 2022 | | 2022 |
| Recurrent BCL10 mutations drive BTK inhibitor resistance in BN2-subtype diffuse large B-cell lymphomas by constitutively activating NF-kB and the MALT1 protease CA Coughlin, P Kumar, ER Roberts, HG Lopez, M Lekakis, L Li, D Bilbao, ... Cancer Research 82 (12_Supplement), 3976-3976, 2022 | | 2022 |
| PI3K/AKT Activation Mediates B-Cell Transformation By the T Splice-Variant of Fyn Kinase P Kumar, L Li, JH Schatz Blood 138 (Supplement 1), 4334-4334, 2021 | | 2021 |
